82. Taura K, Yamamoto Y, Nakajima A, Hata K, Uchinami H, Yonezawa K, Hatano E, Nishino N,
Yamaoka Y (2004) Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228
(FK228), on adenovirus-mediated transgene expression. J Gene Med 6(5):526–536
83. Yasukawa K, Sawamura D, Goto M, Nakamura H, Shimizu H (2007) Histone deacetylase
inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Br J Dermatol 157(4):662–669
84. Murakami K, Matsubara H, Hoshino I, Akutsu Y, Miyazawa Y, Matsushita K, Sakata H,
Nishimori T, Usui A, Kano M, Nishino N, Yoshida M (2010) CHAP31 induces apoptosis
only via the intrinsic pathway in human esophageal cancer cells. Oncology 78(1):62–74
85. Isozaki Y, Hoshino I, Nohata N, Kinoshita T, Akutsu Y, Hanari N, Mori M, Yoneyama Y,
Akanuma N, Takeshita N, Maruyama T, Seki N, Nishino N, Yoshida M, Matsubara H (2012)
Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by
histone acetylation in esophageal squamous cell carcinoma. Int J Oncol 41(3):985–994
86. Fujii S, Okinaga T, Ariyoshi W, Takahashi O, Iwanaga K, Nishino N, Tominaga K, Nishihara T
(2013) Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybridcompound histone deacetylase inhibitor. Biochem Biophys Res Commun 434(3):413–420
87. Hutt DM, Olsen CA, Vickers CJ, Herman D, Chalfant MA, Montero A, Leman LJ, Burkle R,
Maryanoff BE, Balch WE, Ghadiri MR (2011) Potential agents for treating cystic fibrosis:
cyclic tetrapeptides that restore trafficking and activity of ΔF508-CFTR. ACS Med Chem Lett
2(9):703–707
88. Lai J-I, Leman LJ, Ku S, Vickers CJ, Olsen CA, Montero A, Ghadiri MR, Gottesfeld JM (2017)
Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy:
screening with IPSC-derived neuronal cells. Bioorg Med Chem Lett 27(15):3289–3293
89. Kahnberg P, Lucke AJ, Glenn MP, Boyle GM, Tyndall JD, Parsons PG, Fairlie DP (2006)
Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from α-aminosuberic acid. J Med Chem 49(26):7611–7622
90. Andrews KT, Tran TN, Lucke AJ, Kahnberg P, Le GT, Boyle GM, Gardiner DL, SkinnerAdams TS, Fairlie DP (2008) Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob Agents Chemother 52(4):1454–1461
91. Taddei M, Cini E, Giannotti L, Giannini G, Battistuzzi G, Vignola D, Vesci L, Cabri W (2014)
Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
Bioorg Med Chem Lett 24(1):61–64
92. Krieger V, Hamacher A, Gertzen CG, Senger J, Zwinderman MR, Marek M, Romier C, Dekker
FJ, Kurz T, Jung M, Gohlke H, Kassack MU, Hansen FK (2017) Design, multicomponent
synthesis and anticancer activity of a focused histone deacetylase (HDAC) inhibitor library with
peptoid-based cap groups. J Med Chem 60(13):5493–5506
93. Belvedere S, Witter DJ, Yan J, Secrist JP, Richon V, Miller TA (2007) Aminosuberoyl
hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. Bioorg Med Chem Lett
17(14):3969–3971
94. Watson PJ, Fairall L, Santos GM, Schwabe JW (2012) Structure of HDAC3 bound to corepressor and inositol tetraphosphate. Nature 481(7381):335–340
95. Millard CJ, Watson PJ, Celardo I, Gordiyenko Y, Cowley SM, Robinson CV, Fairall L,
Schwabe JWR (2013) Class I HDACs share a common mechanism of regulation by inositol
phosphates. Mol Cell 51(1):57–67
96. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon A-M, Schlegl J,
Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dümpelfeld B, Eberhard D,
Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U,
Neubauer G, Ramsden NG, Drewes G (2011) Chemoproteomics profiling of HDAC inhibitors
reveals selective targeting of HDAC complexes. Nat Biotechnol 29(3):255–265
97. Becher I, Dittmann A, Savitski MM, Hopf C, Drewes G, Bantscheff M (2014)
Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem Biol 9(8):1736–1746
Hydroxamic Acid-Containing Peptides in the Study of Histone Deacetylases
53
Yamaoka Y (2004) Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228
(FK228), on adenovirus-mediated transgene expression. J Gene Med 6(5):526–536
83. Yasukawa K, Sawamura D, Goto M, Nakamura H, Shimizu H (2007) Histone deacetylase
inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Br J Dermatol 157(4):662–669
84. Murakami K, Matsubara H, Hoshino I, Akutsu Y, Miyazawa Y, Matsushita K, Sakata H,
Nishimori T, Usui A, Kano M, Nishino N, Yoshida M (2010) CHAP31 induces apoptosis
only via the intrinsic pathway in human esophageal cancer cells. Oncology 78(1):62–74
85. Isozaki Y, Hoshino I, Nohata N, Kinoshita T, Akutsu Y, Hanari N, Mori M, Yoneyama Y,
Akanuma N, Takeshita N, Maruyama T, Seki N, Nishino N, Yoshida M, Matsubara H (2012)
Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by
histone acetylation in esophageal squamous cell carcinoma. Int J Oncol 41(3):985–994
86. Fujii S, Okinaga T, Ariyoshi W, Takahashi O, Iwanaga K, Nishino N, Tominaga K, Nishihara T
(2013) Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybridcompound histone deacetylase inhibitor. Biochem Biophys Res Commun 434(3):413–420
87. Hutt DM, Olsen CA, Vickers CJ, Herman D, Chalfant MA, Montero A, Leman LJ, Burkle R,
Maryanoff BE, Balch WE, Ghadiri MR (2011) Potential agents for treating cystic fibrosis:
cyclic tetrapeptides that restore trafficking and activity of ΔF508-CFTR. ACS Med Chem Lett
2(9):703–707
88. Lai J-I, Leman LJ, Ku S, Vickers CJ, Olsen CA, Montero A, Ghadiri MR, Gottesfeld JM (2017)
Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy:
screening with IPSC-derived neuronal cells. Bioorg Med Chem Lett 27(15):3289–3293
89. Kahnberg P, Lucke AJ, Glenn MP, Boyle GM, Tyndall JD, Parsons PG, Fairlie DP (2006)
Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from α-aminosuberic acid. J Med Chem 49(26):7611–7622
90. Andrews KT, Tran TN, Lucke AJ, Kahnberg P, Le GT, Boyle GM, Gardiner DL, SkinnerAdams TS, Fairlie DP (2008) Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob Agents Chemother 52(4):1454–1461
91. Taddei M, Cini E, Giannotti L, Giannini G, Battistuzzi G, Vignola D, Vesci L, Cabri W (2014)
Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
Bioorg Med Chem Lett 24(1):61–64
92. Krieger V, Hamacher A, Gertzen CG, Senger J, Zwinderman MR, Marek M, Romier C, Dekker
FJ, Kurz T, Jung M, Gohlke H, Kassack MU, Hansen FK (2017) Design, multicomponent
synthesis and anticancer activity of a focused histone deacetylase (HDAC) inhibitor library with
peptoid-based cap groups. J Med Chem 60(13):5493–5506
93. Belvedere S, Witter DJ, Yan J, Secrist JP, Richon V, Miller TA (2007) Aminosuberoyl
hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. Bioorg Med Chem Lett
17(14):3969–3971
94. Watson PJ, Fairall L, Santos GM, Schwabe JW (2012) Structure of HDAC3 bound to corepressor and inositol tetraphosphate. Nature 481(7381):335–340
95. Millard CJ, Watson PJ, Celardo I, Gordiyenko Y, Cowley SM, Robinson CV, Fairall L,
Schwabe JWR (2013) Class I HDACs share a common mechanism of regulation by inositol
phosphates. Mol Cell 51(1):57–67
96. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon A-M, Schlegl J,
Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dümpelfeld B, Eberhard D,
Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U,
Neubauer G, Ramsden NG, Drewes G (2011) Chemoproteomics profiling of HDAC inhibitors
reveals selective targeting of HDAC complexes. Nat Biotechnol 29(3):255–265
97. Becher I, Dittmann A, Savitski MM, Hopf C, Drewes G, Bantscheff M (2014)
Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem Biol 9(8):1736–1746
Hydroxamic Acid-Containing Peptides in the Study of Histone Deacetylases
53